A New Dawn in Breast Cancer Treatment: Ultra-Hypofractionated Radiotherapy

By HEOR Staff Writer

December 8, 2023

A Shift in Radiotherapy Practices

Breast cancer treatment often includes radiotherapy. Traditionally, patients in Ireland underwent a moderately hypofractionated regimen, involving 15 sessions over three weeks. Recent clinical trials, however, have explored the efficacy of an ultra-hypofractionated regimen: five sessions over one week, with larger doses per session. Such a shift in practice requires justification by the Health Information and Quality Authority (HIQA) under Irish law, ensuring that the benefits outweigh the risks.

Evidence Review and Expert Input

To justify this practice, HIQA reviewed medical literature and consulted experts, including a patient representative. Considerations included side effects, quality of life, cosmetic outcome, and the effectiveness of ultra-hypofractionated radiotherapy compared to its moderately hypofractionated counterpart. Occupational and public radiation safety issues were also evaluated. The evidence indicates that for suitable patients, ultra-hypofractionated radiotherapy is as effective and safe as the traditional method.

Advantages of Ultra-Hypofractionated Radiotherapy

A significant advantage of ultra-hypofractionated radiotherapy is the reduced hospital visits for patients, from 15 sessions over three weeks to just five sessions over one week. While both regimens have associated side effects, studies indicate no significant differences between them. After reviewing the risks and benefits, HIQA justified the practice of ultra-hypofractionated radiotherapy for breast cancer.

Evidence Synthesis Process

HIQA’s evidence synthesis process involved a targeted search of grey literature sources. They identified twelve guidelines from professional bodies and organisations specific to various countries. They found two key clinical guidelines relevant to their research questions. HIQA used the risk of bias in systematic reviews (ROBIS) tool to appraise the systematic review in the NICE clinical guideline.

In Conclusion

The shift towards ultra-hypofractionated radiotherapy represents a significant advance in breast cancer treatment. The practice not only reduces the treatment burden for patients but also maintains the same level of effectiveness and safety as the traditional approach. As always, the choice of treatment should be tailored to the individual patient’s characteristics, ensuring the best possible outcome.

Reference url

Recent Posts

FDA Cancer Trial Guidelines: Prioritizing Overall Survival for Patient-Centered Approvals

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift focus from surrogate measures like progression-free s...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy
Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...